Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Kowa Company, Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Kowa Company, Ltd. - Product Pipeline Review - 2014', provides an overview of the Kowa Company, Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Kowa Company, Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Kowa Company, Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Kowa Company, Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Kowa Company, Ltd.'s pipeline products Reasons to buy - Evaluate Kowa Company, Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Kowa Company, Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Kowa Company, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Kowa Company, Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kowa Company, Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Kowa Company, Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Kowa Company, Ltd. Snapshot 5 Kowa Company, Ltd. Overview 5 Key Information 5 Key Facts 5 Kowa Company, Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Kowa Company, Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Kowa Company, Ltd. - Pipeline Products Glance 13 Kowa Company, Ltd. - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Phase III Products/Combination Treatment Modalities 14 Kowa Company, Ltd. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Kowa Company, Ltd. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Kowa Company, Ltd. - Drug Profiles 19 ripasudil 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 K-103IP 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 K-877 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 peretinoin 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 anagliptin 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 K-134 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 K-828-AB 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 pitavastatin CR 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 epirubicin hydrochloride 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 K-312 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Acyl-Coenzyme A Inhibitor 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 K-163SZ 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Kowa Company, Ltd. - Pipeline Analysis 33 Kowa Company, Ltd. - Pipeline Products by Target 33 Kowa Company, Ltd. - Pipeline Products by Route of Administration 35 Kowa Company, Ltd. - Pipeline Products by Molecule Type 36 Kowa Company, Ltd. - Pipeline Products by Mechanism of Action 37 Kowa Company, Ltd. - Recent Pipeline Updates 39 Kowa Company, Ltd. - Dormant Projects 42 Kowa Company, Ltd. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Kowa Company, Ltd., Key Information 5 Kowa Company, Ltd., Key Facts 5 Kowa Company, Ltd. - Pipeline by Indication, 2014 8 Kowa Company, Ltd. - Pipeline by Stage of Development, 2014 9 Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2014 10 Kowa Company, Ltd. - Partnered Products in Pipeline, 2014 11 Kowa Company, Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12 Kowa Company, Ltd. - Pre-Registration, 2014 13 Kowa Company, Ltd. - Phase III, 2014 14 Kowa Company, Ltd. - Phase II, 2014 15 Kowa Company, Ltd. - Phase I, 2014 16 Kowa Company, Ltd. - Preclinical, 2014 17 Kowa Company, Ltd. - Discovery, 2014 18 Kowa Company, Ltd. - Pipeline by Target, 2014 34 Kowa Company, Ltd. - Pipeline by Route of Administration, 2014 35 Kowa Company, Ltd. - Pipeline by Molecule Type, 2014 36 Kowa Company, Ltd. - Pipeline Products by Mechanism of Action, 2014 38 Kowa Company, Ltd. - Recent Pipeline Updates, 2014 39 Kowa Company, Ltd. - Dormant Developmental Projects,2014 42 Kowa Company, Ltd., Other Locations 43 Kowa Company, Ltd., Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.